United Therapeutics Corp (STU:UTH)
€ 251 -5 (-1.95%) Market Cap: 11.20 Bil Enterprise Value: 9.25 Bil PE Ratio: 12.90 PB Ratio: 2.26 GF Score: 87/100

United Therapeutics Corp at Oppenheimer Healthcare Conference Transcript

Mar 19, 2019 / 05:35PM GMT
Release Date Price: €104.15 (-0.02%)
Hartaj Singh
Oppenheimer & Co. Inc., Research Division - Research Analyst

(technical difficulty)

For joining us here at the United Therapeutics fireside chat. Martine and I would have kept on talking for at least another 10, 15 minutes if we hadn't been told that it's time to go. But I really do appreciate you being here. James also making it down to our conference and looking forward to this fireside chat.

So, Martine, what I thought this time around is we just kind of change things up a little bit and sort of being relentlessly focused on -- when I talk to most companies, I look at sales, I look at earnings and then we talk pipeline.

This time, we talk pipeline. In the last 2 years, you have potentially transformed like UT's pipeline from being heavily dependent on your current commercial products and sort of building them out, right? Each one, sort of, being a core product and you adding more indications and more ways of delivering treprostinil on to them to now looking at different indications; looking at different therapeutic areas, oncology; also looking at sort of

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot